{"id":8743,"date":"2026-06-21T20:01:34","date_gmt":"2026-06-21T14:31:34","guid":{"rendered":"https:\/\/www.entrepreneurindia.co\/blogs\/?p=8743"},"modified":"2026-06-21T20:01:34","modified_gmt":"2026-06-21T14:31:34","slug":"api-manufacturing-plant-in-india","status":"publish","type":"post","link":"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/","title":{"rendered":"API MANUFACTURING: Setting Up an Active Pharmaceutical Ingredient Plant in India: The Complete Guide"},"content":{"rendered":"<p><em>API Manufacturing Plant in India<\/em><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#The_Pill_Behind_Every_Pill\" >The Pill Behind Every Pill<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Get_Detailed_Insights_from_This_Book_Drugs_Pharmaceutical_Technology_Handbook\" >Get Detailed Insights from This Book: Drugs &amp; Pharmaceutical Technology Handbook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#The_Supply_Gap_Nobody_Is_Talking_About_Enough\" >The Supply Gap Nobody Is Talking About Enough<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#TABLE_1_Key_API_Pharma_Clusters_in_India_%E2%80%94_Demand_Capacity_Import_Gap\" >TABLE 1: Key API Pharma Clusters in India \u2014 Demand, Capacity &amp; Import Gap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Why_the_Window_Is_Open_Right_Now\" >Why the Window Is Open Right Now<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Get_Detailed_Project_Report_DPR_Active_Pharmaceutical_Ingredient_API_Products_Bulk_API_Manufacturing\" >Get Detailed Project Report (DPR): Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step-by-Step_Setting_Up_Your_API_Unit\" >Step-by-Step: Setting Up Your API Unit<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_1_Choose_Your_API_Category\" >Step 1: Choose Your API Category<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_2_Location_Decision\" >Step 2: Location Decision<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_3_Machinery_Equipment\" >Step 3: Machinery &amp; Equipment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_4_Raw_Material_Sourcing\" >Step 4: Raw Material Sourcing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_5_Licences_Regulatory_Approvals\" >Step 5: Licences &amp; Regulatory Approvals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Step_6_Team_Requirements\" >Step 6: Team Requirements<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Related_Article_Specialty_Chemicals_Pharmaceutical_API_Manufacturing_Business_in_India_%E2%80%93_Investment_Guide\" >Related Article: Specialty Chemicals &amp; Pharmaceutical API Manufacturing Business in India \u2013 Investment Guide<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#TABLE_2_Investment_Breakdown_for_a_Small-Scale_API_Unit_Chemical_Synthesis_100%E2%80%93200_TPA\" >TABLE 2: Investment Breakdown for a Small-Scale API Unit (Chemical Synthesis, 100\u2013200 TPA)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Financial_Snapshot_What_the_Numbers_Actually_Look_Like\" >Financial Snapshot: What the Numbers Actually Look Like<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#TABLE_3_Government_Schemes_Applicable_to_API_Bulk_Drug_Manufacturing_Units\" >TABLE 3: Government Schemes Applicable to API \/ Bulk Drug Manufacturing Units<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#ENTREPRENEUR_SPOTLIGHT\" >ENTREPRENEUR SPOTLIGHT<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Build_a_profitable_business_with_the_right_idea\" >Build a profitable business with the right idea<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Planning_Your_Project_Where_to_Find_Serious_Technical_Support\" >Planning Your Project: Where to Find Serious Technical Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#The_Next_Step_Is_Specific_Not_General\" >The Next Step Is Specific, Not General<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.entrepreneurindia.co\/blogs\/api-manufacturing-plant-in-india\/#KEY_CITATIONS_DATA_SOURCES\" >KEY CITATIONS &amp; DATA SOURCES<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"The_Pill_Behind_Every_Pill\"><\/span><strong>The Pill Behind Every Pill<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Each tablet that your local chemist dispenses is based on something that few people know about: the Active Pharmaceutical Ingredient, or molecule that performs the therapeutic action. The painful reality is that India is 43% dependent on China for APIs, the self-proclaimed &#8216;Pharmacy of the World&#8217;, says data from the Pharmaceutical Exports Promotion Council (<a href=\"https:\/\/www.pharmexcil.com\" target=\"_blank\" rel=\"noopener\">Pharmexcil<\/a>). That dependence is essentially 100% for 25 to 35 specific categories of APIs, such as critical antibiotics like Penicillin G, cephalosporins and the intermediates of rifampicin.<\/p>\n<p>This is no fringe finding. The India government&#8217;s own <a href=\"https:\/\/mocf.gov.in\/\" target=\"_blank\" rel=\"noopener\">ministry of Chemicals &amp; Fertilizers<\/a> has admitted it in Parliament. Imports from China climbed from \u20b918,646 crore in 2020-21 to \u20b927,032 crore in 2024-25, a rise of roughly 45% in five years. Indian formulation manufacturers try to pay off spot prices every time Chinese environmental authorities close a plant \u2013 as they have done many times over the last decade. Margins collapse. Medicines are in short supply.<\/p>\n<p>Now that&#8217;s the weakness that&#8217;s soaking up the opportunity! The government has set aside \u20b96,940 crore under PLI scheme to turn this trend. There are 3 established Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh, with construction works in progress. There is a trend toward de-China-ization of supply chains for the US and European buyers. The molecule-making business is open now in India, and if you want to make a small but viable API business, you can start from about \u20b93.5 crore.<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Get_Detailed_Insights_from_This_Book_Drugs_Pharmaceutical_Technology_Handbook\"><\/span>Get Detailed Insights from This Book: <a href=\"https:\/\/www.niir.org\/books\/book\/drugs-pharmaceutical-technology-handbook\/isbn-8178330547\/zb,,82,a,0,0,a\/index.html\" target=\"_blank\" rel=\"noopener\">Drugs &amp; Pharmaceutical Technology Handbook<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"The_Supply_Gap_Nobody_Is_Talking_About_Enough\"><\/span><strong>The Supply Gap Nobody Is Talking About Enough<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>India exported pharmaceuticals worth over \u20b92.06 lakh crore in 2023-24, according to Pharmexcil data. It accounts for 20% of the world&#8217;s generics market turnover. However, the raw material for such formulations \u2014 the APIs \u2014 is coming in far more from one country. API imports in India for FY 2024 were valued at \u20b937700 crores of which China accounted for \u20b927032 crores.<\/p>\n<p>The weakness of the structure is multi-layered. The first is the cost, Chinese manufacturers, with government supports and huge volumes, are manufacturing the commodity API on the whole at prices which the Indian small-scale producers could never compete on. The price of Paracetamol API has dipped to \u20b9250\/kg from \u20b9900\/kg during the peak of the pandemic. Second, it&#8217;s concentration: India has almost complete dependence on China for pyridine compounds, barbituric acid derivatives, sulphonamides and key intermediates for penicillin and cephalosporin, says <a href=\"http:\/\/www.dgciskol.gov.in\" target=\"_blank\" rel=\"noopener\">Directorate General of Commercial Intelligence and Statistics (DGCI&amp;S)<\/a>.<\/p>\n<p>There are entire API categories that Indian formulation companies desperately want, and that is where opportunity is to be found, third. Domestically, a number of chronically undersupplied APIs include cardiovascular, anti-diabetic, oncology intermediates, and specialty fermentation-based APIs. The clusters that are the worst hit: Hyderabad (Telangana) has more than 40% of India&#8217;s formulation capacity, but is almost dependent on imported APIs, Baddi\u2013Barotiwala\u2013Nalagarh in Himachal Pradesh produces every third medicine sold in the country and the Vapi\u2013Ankleshwar corridor in Gujarat is a key chemical and pharma manufacturing belt already geared up for handling hazardous chemicals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"TABLE_1_Key_API_Pharma_Clusters_in_India_%E2%80%94_Demand_Capacity_Import_Gap\"><\/span><strong>TABLE 1: Key API Pharma Clusters in India \u2014 Demand, Capacity &amp; Import Gap<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>State \/ Cluster<\/strong><\/td>\n<td><strong>Pharma Cluster<\/strong><\/td>\n<td><strong>Formulation Units<\/strong><\/td>\n<td><strong>Dominant Import Dependency<\/strong><\/td>\n<td><strong>Key APIs Needed Locally<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Telangana<\/td>\n<td>Hyderabad (Genome Valley)<\/td>\n<td>750+<\/td>\n<td>70\u201380% APIs from China<\/td>\n<td>Oncology, CVS, anti-infective APIs<\/td>\n<\/tr>\n<tr>\n<td>Himachal Pradesh<\/td>\n<td>Baddi\u2013Barotiwala\u2013Nalagarh<\/td>\n<td>650+<\/td>\n<td>75\u201380% APIs imported<\/td>\n<td>Paracetamol, antibiotic APIs, vitamins<\/td>\n<\/tr>\n<tr>\n<td>Gujarat<\/td>\n<td>Vapi\u2013Ankleshwar\u2013Bharuch<\/td>\n<td>500+<\/td>\n<td>60\u201370% APIs from imports<\/td>\n<td>Chemical synthesis APIs, specialty molecules<\/td>\n<\/tr>\n<tr>\n<td>Maharashtra<\/td>\n<td>Pune\u2013Aurangabad belt<\/td>\n<td>400+<\/td>\n<td>65% dependence on imports<\/td>\n<td>Hormonal, neurological APIs<\/td>\n<\/tr>\n<tr>\n<td>Rajasthan<\/td>\n<td>Udaipur\u2013Jaipur RIICO parks<\/td>\n<td>150+<\/td>\n<td>55% import dependence<\/td>\n<td>Anti-diabetic, anti-malarial APIs<\/td>\n<\/tr>\n<tr>\n<td>Andhra Pradesh<\/td>\n<td>Visakhapatnam\u2013Kakinada<\/td>\n<td>200+<\/td>\n<td>Bulk Drug Park under construction<\/td>\n<td>Fermentation APIs, penicillin derivs.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Sources: Pharmexcil, DGCI&amp;S, Department of Pharmaceuticals (DoP)<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_the_Window_Is_Open_Right_Now\"><\/span><strong>Why the Window Is Open Right Now<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The API manufacturing entry is a more compelling case than ever in the last 10 years as three forces are coming together at the same moment.<\/p>\n<ol>\n<li><strong> The US Biosecure Act effect.<\/strong> In the wake of the US Biosecure Act, which has banned federal contractors from using certain Chinese biotech companies, American buyers are eager to move away from dependence on China. <a href=\"https:\/\/www.mordorintelligence.com\/industry-reports\/india-active-pharmaceutical-ingredients-market\" target=\"_blank\" rel=\"noopener\">Mordor Intelligence<\/a> market data indicated that there was a 50% rise in the number of RFQs received by Indian contract API manufacturers in 2024. This is the direction in which Europe is going. Producers of domestic API in India who are located in the vicinity of existing hubs of API production will benefit directly.<\/li>\n<li><strong> PLI Scheme for Bulk Drugs \u2014 \u20b96,940 crore in the coffers.<\/strong> The Department of Pharmaceuticals manages the Production Linked Incentive (PLI) Scheme which includes incentives for incremental domestic sales of 41 identified critical APIs and KSMs for a period of 6 years. Of the 41 products, 33 have been subscribed and 48 greenfield projects approved. Committed investment is at \u20b94,329.95 crore, but actual investment has already crossed over \u20b94,814 crore, indicating that the market is going past the scheme&#8217;s own targets.<\/li>\n<li><strong> Subsidy for bulk Drug Park \u2014 70-90% of the cost of Infrastructure covered. <\/strong>The common infrastructure of these three parks\u2014 effluent treatment plant, power sub-station, road, warehousing and utility connection\u2014is being funded by the centre in these three parks (East Godavari, Gujarat-Bharuch and Himachal Pradesh-Una) under a Scheme for Promotion of Bulk Drug Parks (outlay of \u20b93,000 crore). Within these parks, units can be deployed with OSIplug and play infrastructure at a significantly lower price. The cost of the infrastructure in the hilly state of Himachal Pradesh is 90% funded by the government.<\/li>\n<li><strong> Access to credit by 4. MUDRA and CGTMSE.<\/strong> The collateral-free loan facilities available to MSME API units include MUDRA (Tarun category) loan of up to \u20b92 crore and collateral-free loan facilities, provided through Credit Guarantee Trust for Micro and Small Enterprises (CGTMSE) which provides guarantees to banks for lending to MSMEs without requiring any physical collateral. This reduces the amount of capital that is needed for the first-generation entrepreneurs.<\/li>\n<\/ol>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Get_Detailed_Project_Report_DPR_Active_Pharmaceutical_Ingredient_API_Products_Bulk_API_Manufacturing\"><\/span>Get Detailed Project Report (DPR): <a href=\"https:\/\/www.niir.org\/profile-projects-reports\/profiles\/active-pharmaceutical-ingredient-api-products-bulk-api-manufacturing\/z,,e6,0,a\/index.html\" target=\"_blank\" rel=\"noopener\">Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<figure id=\"attachment_8745\" aria-describedby=\"caption-attachment-8745\" style=\"width: 1200px\" class=\"wp-caption alignnone\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-8745\" src=\"https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112.jpg\" alt=\"API Manufacturing Plant in India with pharmaceutical production equipment and bulk drug manufacturing facility\" width=\"1200\" height=\"1800\" srcset=\"https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112.jpg 1200w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-200x300.jpg 200w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-683x1024.jpg 683w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-768x1152.jpg 768w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-1024x1536.jpg 1024w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-150x225.jpg 150w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-750x1125.jpg 750w, https:\/\/www.entrepreneurindia.co\/blogs\/wp-content\/uploads\/2026\/06\/Untitled-design-2026-06-21T194119.112-1140x1710.jpg 1140w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><figcaption id=\"caption-attachment-8745\" class=\"wp-caption-text\">A modern API manufacturing plant in India producing Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.<\/figcaption><\/figure>\n<h2><span class=\"ez-toc-section\" id=\"Step-by-Step_Setting_Up_Your_API_Unit\"><\/span><strong>Step-by-Step: Setting Up Your API Unit<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Step_1_Choose_Your_API_Category\"><\/span><strong>Step 1: Choose Your API Category<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Some APIs are simpler and require less capital than others. Chemical synthesis APIs are the focus of new players, not fermentation-based APIs. Conventional organic chemistry reactors are necessary to make the chemical synthesis APIs, as well as paracetamol, metformin, aspirin or ibuprofen, and are much simpler to licence, operate and quality certify than fermentation processes (antibiotics, enzymes). Begin with one molecule or two that are familiar and have stable domestic demand in a formulation cluster in close proximity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_2_Location_Decision\"><\/span><strong>Step 2: Location Decision<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It is highly recommended to set up in a designated pharmaceutical industrial park or GIDC estate (Gujarat), APICOL estate (Andhra Pradesh) or HIMUDA estate (Himachal Pradesh). The areas have been provided with pre-sanctioned Consent to Establish from the State Pollution Control Board, common effluent treatment plants (CETP), bonded warehousing and shorter time for obtaining licences. Small API unit size: 2,000 \u2013 5,000 sq ft built up area (production + QC lab + storage). Greenfield land requirement (ETP and open area buffer): 0.5-1 acre minimum.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_3_Machinery_Equipment\"><\/span><strong>Step 3: Machinery &amp; Equipment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Small Chemical Synthesis API Plant \u2013 Core Equipment:<\/p>\n<ul>\n<li>Stainless steel reactors (SS-316L): 2 \u00d7 1 KL capacity \u2014 \u20b918\u201325 lakh each<\/li>\n<li>Nutsche filter \/ filter dryer: \u20b912-18 lakh<\/li>\n<li>Vacuum Distillation Unit: \u20b98\u201312 lakh.<\/li>\n<li>Multi-effect evaporator (for solvent recovery): \u20b910-15 lakh<\/li>\n<li>Suitable laboratory instruments (HPLC, UV-Vis, Karl Fischer etc): \u20b925-35 lakh<\/li>\n<li>ETP (Effluent Treatment Plant): If not on CETP then \u20b915\u201325 lakh.<\/li>\n<\/ul>\n<p>The major equipment suppliers are based in Pune (Godrej Process Equipment), Mumbai (Praj Industries), Ahmedabad (GMM Pfaudler) and Chennai (HLE Glascoat). Most of them have a deferment of payment for MSME buyers registered as Udyam.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_4_Raw_Material_Sourcing\"><\/span><strong>Step 4: Raw Material Sourcing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>KSMs and chemical intermediates are mostly sourced from Gujarat (Ankleshwar &amp; Vapi), Maharashtra (Tarapur &amp; Dombivali MIDC) and Rajasthan. By starting the production process with the involvement of two or three domestic KSM traders, building suppliers can reduce risks in the supply chain. <a href=\"https:\/\/www.indianchemicalcouncil.com\" target=\"_blank\" rel=\"noopener\">Indian Chemical Council (ICC)<\/a> has a vendor directory for sourcing verification of specialty solvents and reagents.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_5_Licences_Regulatory_Approvals\"><\/span><strong>Step 5: Licences &amp; Regulatory Approvals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Udyam Registration (MSME portal)<\/strong> \u2014 Free and Online Registration, Instant Registration. Do this first.<\/p>\n<p><strong>CDSCO Drug Manufacturing Licence (Form 25\/28) <\/strong>through State Drug Controller. Permission under API (Form CT-13) &#8211; Government fee \u20b95,000. The official website of the CDSCO is cdsco.gov.in.The CDSCO SUGAM website is cdsco.gov.in.<\/p>\n<p><strong>State Pollution Control Board <\/strong>\u2014 Consent to Establish (CTE) &amp; Consent to Operate (CTO). API units fall under &#8216;Red Category&#8217; industries. Allow 60\u201390 days.<\/p>\n<p><strong>Factory Licence<\/strong> \u2013 issued by the State Labour\/Factories Inspectorate in accordance with the Factories Act 1948. Must be done when the number of workers exceeds 10 (with power) or 20 (without power).<\/p>\n<p><strong>GST Registration<\/strong> \u2014 mandatory. HSN codes of APIs belong to Chapter 29 (Organic Chemicals) and Chapter 30 (Pharmaceutical Products).<\/p>\n<p><strong>IEC from DGFT (Import Export Code)<\/strong> \u2013 If exports \/ imports of raw material.<\/p>\n<p><strong>WHO-GMP \/ Schedule M compliance<\/strong> \u2013 required for selling to regulated-market formulation units or for export. CDSCO is responsible for GMP inspections.<\/p>\n<p>Time for total licencing: 12 \u2013 18 months if a new unit is well planned.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_6_Team_Requirements\"><\/span><strong>Step 6: Team Requirements<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>To start operations, at least 1 qualified person (B.) is required.Pharm or M.1 QC, 2 production operators, 1 maintenance technician, 1 accounts\/compliance person, 1 Sc Chemistry (required by Drugs &amp; Cosmetics Act). Total: 6\u20138 at start up. Expand to 15\u201320 at 60% capacity.<\/p>\n<h3 class=\"wp-block-heading has-text-align-center\" style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Related_Article_Specialty_Chemicals_Pharmaceutical_API_Manufacturing_Business_in_India_%E2%80%93_Investment_Guide\"><\/span>Related Article: <a href=\"https:\/\/www.niir.org\/blog\/specialty-chemical-manufacturing-india\/\" target=\"_blank\" rel=\"noopener\">Specialty Chemicals &amp; Pharmaceutical API Manufacturing Business in India \u2013 Investment Guide<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"TABLE_2_Investment_Breakdown_for_a_Small-Scale_API_Unit_Chemical_Synthesis_100%E2%80%93200_TPA\"><\/span><strong>TABLE 2: Investment Breakdown for a Small-Scale API Unit (Chemical Synthesis, 100\u2013200 TPA)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>Cost Head<\/strong><\/td>\n<td><strong>Low Estimate (\u20b9)<\/strong><\/td>\n<td><strong>High Estimate (\u20b9)<\/strong><\/td>\n<td><strong>% of Total CapEx<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Land (leased inside industrial estate)<\/td>\n<td>\u20b925 lakh<\/td>\n<td>\u20b960 lakh<\/td>\n<td>10\u201312%<\/td>\n<\/tr>\n<tr>\n<td>Civil Construction (production + QC + store)<\/td>\n<td>\u20b940 lakh<\/td>\n<td>\u20b980 lakh<\/td>\n<td>15\u201318%<\/td>\n<\/tr>\n<tr>\n<td>Reactors, Dryers &amp; Core Equipment<\/td>\n<td>\u20b980 lakh<\/td>\n<td>\u20b91.50 crore<\/td>\n<td>28\u201332%<\/td>\n<\/tr>\n<tr>\n<td>QC Laboratory Setup<\/td>\n<td>\u20b925 lakh<\/td>\n<td>\u20b950 lakh<\/td>\n<td>9\u201311%<\/td>\n<\/tr>\n<tr>\n<td>ETP \/ Pollution Control System<\/td>\n<td>\u20b915 lakh<\/td>\n<td>\u20b930 lakh<\/td>\n<td>6\u20138%<\/td>\n<\/tr>\n<tr>\n<td>Working Capital (6 months raw material + wages)<\/td>\n<td>\u20b960 lakh<\/td>\n<td>\u20b91.20 crore<\/td>\n<td>20\u201322%<\/td>\n<\/tr>\n<tr>\n<td>Licences, Contingency &amp; Pre-operative Expenses<\/td>\n<td>\u20b915 lakh<\/td>\n<td>\u20b925 lakh<\/td>\n<td>5\u20136%<\/td>\n<\/tr>\n<tr>\n<td><strong>TOTAL ESTIMATED CAPEX<\/strong><\/td>\n<td><strong>\u20b92.60 crore<\/strong><\/td>\n<td><strong>\u20b95.15 crore<\/strong><\/td>\n<td><strong>100%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Note: Figures based on a 100\u2013200 TPA chemical synthesis API plant in a pharma industrial estate. Scale and state-specific costs will vary. Source: IMARC Group DPR estimates, NPCS project data.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Financial_Snapshot_What_the_Numbers_Actually_Look_Like\"><\/span><strong>Financial Snapshot: What the Numbers Actually Look Like<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On a representative API chemical synthesis unit of size \u20b93.5 crore and manufacturing capacity of 150TPA of a mid-complexity chemical API:<\/p>\n<ul>\n<li>Monthly operating cost: \u20b918\u201324 lakh (raw materials 55\u201360%, utilities 20%, wages 15%, overheads 10%)<\/li>\n<li>Revenue at 60% capacity: \u20b990\u20131.10 crore per year (assuming \u20b91,000\u20131,200\/kg realization)<\/li>\n<li>Revenue at 100% capacity: \u20b91.50\u20131.80 crore per year<\/li>\n<li>They range from 38% to 48% for APIs (chemical synthesis) and 55% to 65% for APIs (fermentation). APIs with fermentation methods feature higher gross margins but require higher setup costs.<\/li>\n<li>Net margin \u2013 full capacity: 18-24% post depreciation, interest and taxes<\/li>\n<li>Payback period: 4-6 years, for a good location, well managed, lean unit.<\/li>\n<\/ul>\n<p>These figures are in line with the IMARC Group API Manufacturing Plant Project Report, which estimates gross margins of the chemical synthesis APIs at 50\u201365% and net profit at 25\u201340% at full capacity for larger-scale operations. Smaller units are nimbler, have lower margins, but are closer to the customer. Units going to semi regulated markets (Africa\/Southeast Asia) via pharmexcil registered channels can be sold at premium of 12\u201315% above domestic price.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"TABLE_3_Government_Schemes_Applicable_to_API_Bulk_Drug_Manufacturing_Units\"><\/span><strong>TABLE 3: Government Schemes Applicable to API \/ Bulk Drug Manufacturing Units<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td><strong>Scheme<\/strong><\/td>\n<td><strong>Administering Body<\/strong><\/td>\n<td><strong>Benefit \/ Quantum<\/strong><\/td>\n<td><strong>Eligibility<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>PLI \u2014 Bulk Drugs<\/td>\n<td>Dept. of Pharmaceuticals (pharmaceuticals.gov.in)<\/td>\n<td>10\u201320% incentive on incremental sales over 6 years<\/td>\n<td>Greenfield plants producing any of 41 notified APIs\/KSMs<\/td>\n<\/tr>\n<tr>\n<td>Bulk Drug Park Scheme<\/td>\n<td>Dept. of Pharmaceuticals + State Govts.<\/td>\n<td>70\u201390% of common infra cost covered by Centre<\/td>\n<td>Units setting up in approved parks in AP, Gujarat, HP<\/td>\n<\/tr>\n<tr>\n<td>MUDRA \u2013 Tarun Loan<\/td>\n<td>SIDBI \/ Bank branches<\/td>\n<td>Up to \u20b920 lakh (Shishu \u20b950K, Kishor \u20b95L, Tarun \u20b920L)<\/td>\n<td>Micro enterprises; no collateral required<\/td>\n<\/tr>\n<tr>\n<td>CGTMSE<\/td>\n<td>SIDBI + MoMSME (cgtmse.in)<\/td>\n<td>Credit guarantee up to \u20b95 crore (collateral-free)<\/td>\n<td>MSME units with Udyam registration, lending bank participation<\/td>\n<\/tr>\n<tr>\n<td>PMEGP<\/td>\n<td>KVIC \/ KVIB \/ DIC (kviconline.gov.in)<\/td>\n<td>15\u201335% subsidy on project cost up to \u20b950 lakh (mfg.)<\/td>\n<td>New entrepreneurs; not for existing units; mfg. up to \u20b950L project<\/td>\n<\/tr>\n<tr>\n<td>Technology Upgradation Fund (TUF) \u2014 Pharma<\/td>\n<td>Dept. of Pharmaceuticals \/ SIDBI<\/td>\n<td>Interest reimbursement of 5% on machinery loans<\/td>\n<td>MSMEs upgrading to GMP-compliant facilities; Schedule M compliance<\/td>\n<\/tr>\n<tr>\n<td>Startup India \u2014 Tax Exemption (80-IAC)<\/td>\n<td>DPIIT (startupindia.gov.in)<\/td>\n<td>100% tax exemption for 3 consecutive years out of first 10<\/td>\n<td>DPIIT-recognised startups with turnover under \u20b9100 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Sources: Department of Pharmaceuticals (pharmaceuticals.gov.in), SIDBI, KVIC, CGTMSE, DPIIT.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"ENTREPRENEUR_SPOTLIGHT\"><\/span><strong>ENTREPRENEUR SPOTLIGHT<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Macsen Labs Group, Udaipur, Rajasthan<\/strong><\/p>\n<p>In early 2025, Macsen Labs began construction of a new API facility at its RIICO Industrial Area in the town of Gudli, Udaipur, which will be five times as large as its current facility. Its flagship manufacturing plant, Macsen Drugs is USFDA-inspected and has TGA-GMP and WHO-GMP certificates. PLI funding is a part of expansion plan of the company and serves as a blueprint for the MSME origin API businesses to scale their businesses into regulated export markets. The big lesson: Make it GMP compliant from the start \u2014 it will always be more expensive to retrofit.<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Build_a_profitable_business_with_the_right_idea\"><\/span><a href=\"https:\/\/www.niir.org\/startup-selector\" target=\"_blank\" rel=\"noopener\">Build a profitable business with the right idea<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"Planning_Your_Project_Where_to_Find_Serious_Technical_Support\"><\/span><strong>Planning Your Project: Where to Find Serious Technical Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>As an entrepreneur at the feasibility stage, it is critical to get the techno-economic numbers correct before investing the capital. Niir Project Consultancy Services (NPCS) at <a href=\"https:\/\/www.niir.org\" target=\"_blank\" rel=\"noopener\">niir.org<\/a> has published detailed project reports and feasibility studies which are specifically on API and bulk drug manufacturing in India. They include plant layout design, equipment specifications, raw material sourcing maps, margin modelling and regulatory compliance checklists, all of the level of detail that saves months of trial and error. The publication arm of<a href=\"https:\/\/www.entrepreneurindia.co\"> entrepreneurindia.co<\/a> also releases project profiles and sector guides for pharmaceutical manufacturing entrepreneurs for investment planning. For the first time API investors who may have capital but not necessarily the know-how of the sector, NPCS provides end-to-end consultancy in plant design, process selection and techno-economic feasibility studies.<\/p>\n<div class=\"jeg_video_container jeg_video_content\"><iframe title=\"Active Pharmaceutical Ingredients (API Bulk Drugs) Manufacturing Industry\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/dgVwuiiujg0?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<h2><span class=\"ez-toc-section\" id=\"The_Next_Step_Is_Specific_Not_General\"><\/span><strong>The Next Step Is Specific, Not General<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>India&#8217;s API market is no myth. Policy architecture is in place. The demand of formulation clusters can be measured. It has been documented that there is a supply gap from China. The lack of increased MSME capital investment in the manufacturing chain is what is missing.<\/p>\n<p>If you&#8217;re reading this and know that there&#8217;s a molecule you need to bring to market that&#8217;s currently being imported by local formulation companies in your vicinity, and you have a deployable capital of \u20b93-5 crore this week, the number one thing you can do is do a techno-economic feasibility study on one molecule. Contact the State Drug Controller&#8217;s office in your state regarding the licencing requirements. Please check the nearest Bulk Drug Park for availability of plot allocation.<\/p>\n<p>It&#8217;s not the chemistry that&#8217;s hard. The determination to start is.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Q1. What is the minimum investment to set up an API manufacturing unit in India?<\/strong><\/p>\n<p>A small chemical synthesis API unit producing 100\u2013150 TPA can be established with a total CapEx of \u20b92.60\u20135.15 crore, including land, civil construction, core equipment, QC lab, ETP, and six months&#8217; working capital. The lower end assumes setting up inside an existing pharma industrial estate (where common infrastructure is shared). Fermentation-based APIs require significantly higher investment \u2014 typically \u20b98\u201320 crore for a comparable scale, due to bioreactor and sterile processing requirements.<\/p>\n<p><strong>Q2. What licences are compulsory before starting production?<\/strong><\/p>\n<p>At minimum: Drug Manufacturing Licence from the State Drug Controller (Form 25\/28 under D&amp;C Act 1940), Pollution Control Board CTE and CTO (API plants are &#8216;Red Category&#8217;), Factory Licence, GST Registration, and Udyam Registration. If exporting or importing raw materials, an IEC from DGFT is also mandatory. For selling to regulated-market buyers (US, EU), WHO-GMP or Schedule M (revised) compliance certification from CDSCO is additionally required. Apply through the <a href=\"https:\/\/www.cdsco.gov.in\/opencms\/opencms\/en\/Home\/\" target=\"_blank\" rel=\"noopener\">CDSCO SUGAM Portal<\/a>.<\/p>\n<p><strong>Q3. Can raw materials for API manufacturing be sourced domestically?<\/strong><\/p>\n<p>Partially. For many chemical synthesis APIs, primary raw materials and solvents are available from Indian chemical manufacturers in Gujarat (Ankleshwar, Vadodara), Maharashtra (Dombivali, Tarapur), and Rajasthan. However, certain Key Starting Materials (KSMs) \u2014 particularly for antibiotic and anti-infective APIs \u2014 still have to be imported from China. The PLI scheme for Bulk Drugs specifically targets 41 such KSMs for domestic production, and availability will improve as those greenfield units commissioned under the scheme reach full output.<\/p>\n<p><strong>Q4. What profit margins are realistic for a small API unit?<\/strong><\/p>\n<p>A well-run small chemical synthesis API unit can achieve gross margins of 38\u201348% and net margins of 18\u201324% at full capacity. Margins are higher for specialty and niche APIs with fewer domestic competitors. Commodity APIs like paracetamol are subject to price pressure from Chinese imports and are better suited to units operating at scale (500 TPA+) or units located inside subsidised Bulk Drug Parks where infrastructure cost is negligible. The payback period on a correctly capitalized unit is 4\u20136 years.<\/p>\n<p><strong>Q5. Which government schemes specifically support API entrepreneurs?<\/strong><\/p>\n<p>The most impactful schemes are: PLI for Bulk Drugs (10\u201320% incentive on incremental sales), the Bulk Drug Park Scheme (70\u201390% of common infrastructure cost funded by Centre), CGTMSE for collateral-free credit up to \u20b95 crore, and MUDRA Tarun loans up to \u20b920 lakh. Units upgrading to GMP standards can access interest reimbursement under the Technology Upgradation Fund for Pharma. All schemes are coordinated through the <a href=\"https:\/\/pharmaceuticals.gov.in\" target=\"_blank\" rel=\"noopener\">Department of Pharmaceuticals<\/a>. DPIIT-recognised startups in this sector also qualify for 3-year tax exemption under Section 80-IAC.<\/p>\n<p><strong>Q6. Where can I find detailed project reports for API plant setup?<\/strong><\/p>\n<p>NIIR Project Consultancy Services (<a href=\"https:\/\/www.niir.org\" target=\"_blank\" rel=\"noopener\">niir.org<\/a>) publishes comprehensive project reports for API and bulk drug manufacturing, covering plant layout, equipment lists, raw material maps, financial projections, and regulatory compliance frameworks. Entrepreneur India (<a href=\"https:\/\/www.entrepreneurindia.co\">entrepreneurindia.co<\/a>) publishes sector guides for manufacturing entrepreneurs. The <a href=\"https:\/\/pharmaceuticals.gov.in\" target=\"_blank\" rel=\"noopener\">Department of Pharmaceuticals<\/a> website also has scheme documents and investor guides. IMARC Group and Mordor Intelligence publish paid market research reports with detailed DPR sections for those requiring third-party validated financials.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"KEY_CITATIONS_DATA_SOURCES\"><\/span><strong>KEY CITATIONS &amp; DATA SOURCES<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/pharmaceuticals.gov.in\" target=\"_blank\" rel=\"noopener\">Department of Pharmaceuticals, Government of India \u2014 PLI Scheme Updates<\/a> \u2014 Scheme details, investment data, progress reports.<\/p>\n<p><a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2237413\" target=\"_blank\" rel=\"noopener\">Press Information Bureau \u2014 Bulk Drug Park Approvals<\/a> \u2014 Official PIB release on PLI and Bulk Drug Park progress.<\/p>\n<p><a href=\"https:\/\/www.cdsco.gov.in\/opencms\/opencms\/en\/Home\/\" target=\"_blank\" rel=\"noopener\">CDSCO \u2014 Central Drugs Standard Control Organization<\/a> \u2014 Drug manufacturing licence procedures, SUGAM portal, Schedule M.<\/p>\n<p><a href=\"https:\/\/www.pharmexcil.com\" target=\"_blank\" rel=\"noopener\">Pharmexcil \u2014 Pharmaceutical Export Promotion Council<\/a> \u2014 Export and import data, registered exporter lists.<\/p>\n<p><a href=\"https:\/\/www.cgtmse.in\" target=\"_blank\" rel=\"noopener\">CGTMSE \u2014 Credit Guarantee Fund Trust for MSMEs<\/a> \u2014 Collateral-free credit guarantee scheme for MSME manufacturers.<\/p>\n<p><a href=\"https:\/\/www.indianchemicalcouncil.com\" target=\"_blank\" rel=\"noopener\">Indian Chemical Council (ICC)<\/a> \u2014 Raw material supplier data, chemical manufacturing cluster maps.<\/p>\n<p><a href=\"http:\/\/www.dgciskol.gov.in\" target=\"_blank\" rel=\"noopener\">DGCI&amp;S \u2014 Directorate General of Commercial Intelligence &amp; Statistics<\/a> \u2014 India API import\/export statistics, HS code-wise data.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>API Manufacturing Plant in India The Pill Behind Every Pill Each tablet that your local chemist dispenses is based on something that few people know about: the Active Pharmaceutical Ingredient, or molecule that performs the therapeutic action. The painful reality is that India is 43% dependent on China for APIs, the self-proclaimed &#8216;Pharmacy of the [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":8744,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","override":[{"template":"2","parallax":"1","fullscreen":"1","layout":"right-sidebar","sidebar":"default-sidebar","second_sidebar":"default-sidebar","sticky_sidebar":"1","share_position":"topbottom","share_float_style":"share-monocrhome","show_share_counter":"1","show_view_counter":"1","show_featured":"1","show_post_meta":"1","show_post_author":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"0","post_reading_time_wpm":"300","post_calculate_word_method":"str_word_count","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","show_comment_section":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"0","show_inline_post_related":"0"}],"image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post_position":"meta","trending_post_label":"Trending","sponsored_post_label":"Sponsored by","disable_ad":"0"},"jnews_primary_category":[],"jnews_social_meta":[],"jnews_paywall_metabox":{"paragraph_limit":"2","enable_premium_post":"0","enable_free_post":"0","override_paragraph_limit":"0","enable_preview_post":"0","enable_preview_video":"0"},"jnews_override_counter":{"view_counter_number":"0","share_counter_number":"0","like_counter_number":"0","dislike_counter_number":"0"},"footnotes":""},"categories":[1081,1229,1225],"tags":[2346,913,2345,2344,2347],"class_list":["post-8743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-manufacturing-business-ideas","category-industrial-project-reports","category-pharmaceutical-industry","tag-active-pharmaceutical-ingredient-manufacturing","tag-api-manufacturing","tag-api-manufacturing-business-india","tag-api-manufacturing-plant-in-india","tag-bulk-drug-manufacturing"],"_links":{"self":[{"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/posts\/8743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/comments?post=8743"}],"version-history":[{"count":1,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/posts\/8743\/revisions"}],"predecessor-version":[{"id":8746,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/posts\/8743\/revisions\/8746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/media\/8744"}],"wp:attachment":[{"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/media?parent=8743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/categories?post=8743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.entrepreneurindia.co\/blogs\/wp-json\/wp\/v2\/tags?post=8743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}